USC.edu
Are You a Patient?

Mark Agulnik, MD

Professor of Clinical Medicine

Vice Chair for Faculty Development, Department of Medicine

Section Chief of Sarcomas & Melanoma

Image of Mark Agulnik, MD
Is this your profile? Click to edit
Request an Appointment
Email [email protected]
CTSI Profile

Publications

  • A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma. Invest New Drugs. 2013 Feb; 31(1):145-51.. View in PubMed
  • Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep; 48(9):887-92.. View in PubMed
  • Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib. Chemotherapy. 2012; 58(1):30-3.. View in PubMed
  • New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol. 2012 Dec; 29(4):2481-91.. View in PubMed
  • NCCN Clinical Practice Guidelines Occult primary. J Natl Compr Canc Netw. 2011 Dec; 9(12):1358-95.. View in PubMed
  • Management of neuroendocrine tumors of unknown origin. J Natl Compr Canc Netw. 2011 Dec; 9(12):1397-402.. View in PubMed
  • New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma. Cancer. 2012 Mar 15; 118(6):1486-97.. View in PubMed
  • Targeted therapies in bone sarcomas: current approach and future directions. Expert Opin Investig Drugs. 2011 Jul; 20(7):973-9.. View in PubMed
  • Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011 Jun; 47(6):441-8.. View in PubMed
  • Head and neck cancer: changing epidemiology and public health implications. Oncology (Williston Park). 2010 Sep; 24(10):915-9, 924.. View in PubMed

Similar People